{"quote": {"result": [{"language": "en-US", "region": "US", "quoteType": "EQUITY", "typeDisp": "Equity", "quoteSourceName": "Delayed Quote", "triggerable": false, "customPriceAlertConfidence": "LOW", "currency": "GBp", "exchange": "LSE", "shortName": "MAXCYTE INC COM STK USD0.01 (DI", "longName": "MaxCyte, Inc.", "messageBoardId": "finmb_4048262", "exchangeTimezoneName": "Europe/London", "exchangeTimezoneShortName": "BST", "gmtOffSetMilliseconds": 3600000, "market": "gb_market", "esgPopulated": false, "regularMarketChangePercent": -2.4, "regularMarketPrice": 305.0, "marketState": "POSTPOST", "firstTradeDateMilliseconds": 1459234800000, "priceHint": 2, "epsTrailingTwelveMonths": -0.15, "epsForward": -0.22, "epsCurrentYear": -0.26, "priceEpsCurrentYear": -1173.077, "sharesOutstanding": 103051000, "bookValue": 2.48, "fiftyDayAverage": 380.01, "fiftyDayAverageChange": -75.01001, "fiftyDayAverageChangePercent": -0.19738956, "twoHundredDayAverage": 463.5675, "twoHundredDayAverageChange": -158.5675, "twoHundredDayAverageChangePercent": -0.34205914, "marketCap": 382195520, "forwardPE": -13.863636, "priceToBook": 122.98387, "sourceInterval": 15, "exchangeDataDelayedBy": 15, "averageAnalystRating": "1.4 - Strong Buy", "tradeable": false, "cryptoTradeable": false, "regularMarketChange": -7.5, "regularMarketTime": 1683904589, "regularMarketDayHigh": 310.0, "regularMarketDayRange": "300.0 - 310.0", "regularMarketDayLow": 300.0, "regularMarketVolume": 34817, "regularMarketPreviousClose": 312.5, "bid": 300.0, "ask": 310.0, "bidSize": 0, "askSize": 0, "fullExchangeName": "LSE", "financialCurrency": "USD", "regularMarketOpen": 310.0, "averageDailyVolume3Month": 38584, "averageDailyVolume10Day": 32070, "fiftyTwoWeekLowChange": 25.0, "fiftyTwoWeekLowChangePercent": 0.08928572, "fiftyTwoWeekRange": "280.0 - 650.0", "fiftyTwoWeekHighChange": -345.0, "fiftyTwoWeekHighChangePercent": -0.5307692, "fiftyTwoWeekLow": 280.0, "fiftyTwoWeekHigh": 650.0, "earningsTimestamp": 1683750600, "earningsTimestampStart": 1683750600, "earningsTimestampEnd": 1683750600, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "symbol": "MXCT.L"}], "error": null}, "summary": {"result": [{"assetProfile": {"address1": "9713 Key West Avenue", "address2": "Suite 400", "city": "Rockville", "state": "MD", "zip": "20850", "country": "United States", "phone": "301 944 1700", "website": "https://maxcyte.com", "industry": "Medical Devices", "industryDisp": "Medical Devices", "sector": "Healthcare", "longBusinessSummary": "MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. The company's products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. It also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.", "fullTimeEmployees": 125, "companyOfficers": [{"maxAge": 1, "name": "Mr. Douglas Arthur Doerfler", "age": 66, "title": "Founder, Pres, CEO & Exec. Director", "yearBorn": 1956, "fiscalYear": 2022, "totalPay": {"raw": 1199638, "fmt": "1.2M", "longFmt": "1,199,638"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 6860686, "fmt": "6.86M", "longFmt": "6,860,686"}}, {"maxAge": 1, "name": "Dr. Cenk  Sumen Ph.D.", "age": 48, "title": "Chief Scientific Officer", "yearBorn": 1974, "fiscalYear": 2022, "totalPay": {"raw": 575600, "fmt": "575.6k", "longFmt": "575,600"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Maher  Masoud", "age": 47, "title": "Exec. VP, Gen. Counsel & Sec.", "yearBorn": 1975, "fiscalYear": 2022, "totalPay": {"raw": 612065, "fmt": "612.07k", "longFmt": "612,065"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 436890, "fmt": "436.89k", "longFmt": "436,890"}}, {"maxAge": 1, "name": "Mr. Douglas J. Swirsky CFA, CPA", "age": 53, "title": "Chief Financial Officer", "yearBorn": 1969, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Ronald Evan Holtz CPA, Ph.D.", "age": 64, "title": "Exec. VP of Admin.", "yearBorn": 1958, "fiscalYear": 2021, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Sean  Menarguez", "title": "Director of Investor Relations", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Thomas Michael Ross", "age": 61, "title": "Exec. VP of Global Sales & Marketing", "yearBorn": 1961, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. J. Stark Thompson Ph.D.", "age": 80, "title": "Consultant", "yearBorn": 1942, "fiscalYear": 2021, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. James  Brady Ph.D.", "title": "Sr. VP of Technical Applications & Customer Support", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Sarah Haecker Meeks Ph.D.", "title": "Sr. VP of Bus. Devel.", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}], "auditRisk": 8, "boardRisk": 8, "compensationRisk": 8, "shareHolderRightsRisk": 8, "overallRisk": 8, "governanceEpochDate": 1682899200, "compensationAsOfEpochDate": 1672444800, "maxAge": 86400}}], "error": null}}